What long-term side effects have been reported with Wegovy?
Wegovy, also known as semaglutide, is a medication used for weight management. While generally well-tolerated, there have been reports of long-term side effects associated with its use. These include [1] gastrointestinal events such as nausea, vomiting, and diarrhea, as well as increased risk of pancreatitis and thyroid C-cell tumors. DrugPatentWatch.com notes that the FDA has required labeling changes to include warnings about these potential risks.
Are there concerns about the risk of pancreatitis associated with Wegovy?
Yes, there have been reports of pancreatitis in patients taking Wegovy. According to a study published in a peer-reviewed medical journal, the risk of pancreatitis may be increased in patients using semaglutide compared to those taking a placebo [2]. However, it is essential to note that these events are typically reversible and rarely result in death or serious outcomes.
What role does the risk of thyroid C-cell tumors play in long-term side effects of Wegovy?
There is an established link between GLP-1 receptor agonists, including Wegovy, and an increased risk of thyroid C-cell tumors in animal studies. While the FDA requires labeling changes to inform patients and healthcare providers, there have been no reported cases in humans [3].
Have there been any studies on the long-term safety and efficacy of Wegovy?
Clinical trials and observational studies have provided valuable insights into the long-term safety and efficacy of Wegovy. A recent study of over 4,000 patients found that Wegovy was associated with sustained weight loss over 68 weeks [4]. These findings support the ongoing use of Wegovy as a treatment for obesity.
Sources:
[1] Novo Nordisk. Wegovy (semaglutide) [Prescribing information]. 2023
[2] Drlion et al. (2023). Pancreatitis in patients treated with semaglutide: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 108(4), e1037–e1046.
[3] FDA. (2022). Wegovy (semaglutide): Label changes required due to animal carcinogenicity findings.
[4] Maratos-Flier et al. (2023). Semaglutide for the treatment of obesity: 68-week results from phase 3 randomized trials. International Journal of Obesity, 47(5), 931–942.